A case of Chagas’ disease panniculitis after kidney transplantation

Chagas’ disease carries high morbidity and mortality due to acute parasitemia or cardiac, digestive, cutaneous or neurological chronic lesions. Latin American countries have the majority of infected or at risk people. Transplanted patients using immunosuppressive agents may develop severe and even fatal forms of the disease. The available treatment causes frequent severe side-effects. A 59 years-old woman with end stage renal disease and positive serology for Chagas’ disease, but without any clinical manifestation of this pathology, underwent kidney transplantation from a cadaveric donor and displayed three months later a thigh panniculitis from which a biopsy unveiled amastigote forms of *Trypanosoma cruzi*. The skin lesions disappeared following treatment with benzonidazole, but the drug was discontinued due to severe pancytopenia. Along with this, infection with *E. faecalis* and cytomegalovirus were treated with vancomycin and ganciclovir. The patient kept very well afterwards, with no new skin lesions and with good graft function. One year and three months after the transplant, she had an emergency surgery for an aortic dissecting aneurysm. Irreversible shock and death occurred in the immediate post-surgical period. It was not possible to establish or to rule out a relationship between the tripanosomiasis and the aortic lesions. Chagas’ disease must be remembered in differential diagnosis of several clinical situations in transplant patients, mainly in endemic areas. The treatment can yield good clinical response, but serious side-effects from the drugs may ensue. More effective and better tolerated options are in need for treatment or prophylaxis.

**Abstract**

Chagas’ disease carries high morbidity and mortality due to acute parasitemia or cardiac, digestive, cutaneous or neurological chronic lesions. Latin American countries have the majority of infected or at risk people. Transplanted patients using immunosuppressive agents may develop severe and even fatal forms of the disease. The available treatment causes frequent severe side-effects. A 59 years-old woman with end stage renal disease and positive serology for Chagas’ disease, but without any clinical manifestation of this pathology, underwent kidney transplantation from a cadaveric donor and displayed three months later a thigh panniculitis from which a biopsy unveiled amastigote forms of *Trypanosoma cruzi*. The skin lesions disappeared following treatment with benzonidazole, but the drug was discontinued due to severe pancytopenia. Along with this, infection with *E. faecalis* and cytomegalovirus were treated with vancomycin and ganciclovir. The patient kept very well afterwards, with no new skin lesions and with good graft function. One year and three months after the transplant, she had an emergency surgery for an aortic dissecting aneurysm. Irreversible shock and death occurred in the immediate post-surgical period. It was not possible to establish or to rule out a relationship between the tripanosomiasis and the aortic lesions. Chagas’ disease must be remembered in differential diagnosis of several clinical situations in transplant patients, mainly in endemic areas. The treatment can yield good clinical response, but serious side-effects from the drugs may ensue. More effective and better tolerated options are in need for treatment or prophylaxis.

**Keywords:** Chagas disease; immunosuppressive agents; kidney transplantation.
Chagas disease or American trypanosomiasis is caused in humans by the flagellate protozoan Trypanosoma cruzi. In the acute phase, the parasite predominates circulating in the bloodstream, bringing manifestations such as fever, headache, lymphadenopathy, pallor, shortness of breath, abdominal or chest pain. Severe acute forms are potentially the cause of death. Signs and symptoms may disappear spontaneously in other cases, evolving into the chronic phase, with rare parasites found in the bloodstream. This phase is initially asymptomatic, but it can progress to cardiac, digestive and neurologic involvement.\(^1\),\(^2\)

Worldwide, it is estimated that there are 10 million people infected by Trypanosoma cruzi, and more than 25 million individuals at risk of acquiring the disease, with most living in Latin America. Among those chronically ill, 30% have cardiac disorders and up to 10% have digestive disorders, neurological disorders or combined diseases.\(^1\)

The modes of transmission to humans are the vector, the T. infestans (“kissing bugs”), transfusion and transplacental infection; more recently an oral transmission has been reported, by eating food contaminated with T. cruzi. Less common mechanisms involve laboratory accidents, handling of infected animals, solid organ transplants and maternal milk.\(^1\),\(^2\)

It should be remembered as one of the infectious diseases that can affect immunocompromised patients.\(^3\),\(^4\)

Chagas panniculitis is a skin lesion caused by reactivation of chronic Chagas disease. It occurs predominantly in immunocompromised patients, such as those with human immunodeficiency syndrome and transplanted under regular use of immunosuppressants, while it may appear isolated or associated with changes in other organs or systems.\(^5\),\(^6\)

**Case report**

Female patient, 59, brown skin, with chronic renal failure due to advanced polycystic kidney disease, on a regular program of hemodialysis and investigation for kidney transplantation. She had no cardiac or digestive abnormalities, but showed positive serology for Chagas disease - positive IgG and negative IgM against the 23% panel (Class I) and 8% (Class II). After a year on hemodialysis, she was transferred to continuous ambulatory peritoneal dialysis (CAPD) due to vascular access difficulties. Two weeks later she received a cadaveric renal transplantation, having two mismatches in locus A, two mismatches in locus B and no mismatch in locus DR. She received induction with antithymocyte globulin and maintenance with tacrolimus, mycophenolate mofetil, and prednisone. She continued oligoanuric after transplantation, and remained on CAPD. She required reintervention for ureteral necrosis, being submitted to graft pelvis anastomosis with the native ureter and she received a Double J catheter. As of the 14\(^{th}\) postoperative day, she was started on allopurinol at a dose of 100 mg per day. A graft biopsy on the 17\(^{th}\) postoperative day showed findings consistent with acute tubular necrosis and no elements indicative of cellular or antibody-mediated rejection; C4d was negative. From the 25\(^{th}\) day, she developed a progressive increase in diuresis and reduction in plasma creatinine, having her peritoneal dialysis suspended, but keeping the peritoneal catheter. Her plasma creatinine was 3.6 mg/dl in the 30\(^{th}\) postoperative day.

Two months after the transplant, she presented clinical symptoms of graft pyelonephritis; urine culture identified E. faecalis. The Double-J was removed and she received vancomycin treatment, with excellent clinical response.

Her serum creatinine remained between 2.5 and 3.0 mg/dl in that period. We also decided to maintain her peritoneal catheter, since she did not have any evidence of abdominal infection or catheter-related infection, and had no hemodialysis vascular access.

At three months’ post-transplant, she reported dark spots on the left thigh, without fever or other symptoms. She had erythematous-violet plaques of infiltrative aspect, slightly painful, of 3 to 4 cm in diameter, on the described location (Figure 1). Biopsy of the lesions showed dermis and hypodermis with multiple histiocytes of large volume cytoplasm, phagocytosing microorganisms morphologically consistent with T. cruzi amastigotes (Figures 2, 3 and 4).

She was started on benznidazole (7 mg/kg/day, divided into two daily doses), with treatment planned for 60 days. Her skin lesions improved progressively.

After 30 days of benznidazole, she developed fever and clinical signs of peritonitis. We infused and drained peritoneal dialysis fluid, which culture again identified E. faecalis, still sensitive to the
vancomycin used for treatment. We removed the peritoneal dialysis catheter. There was complete resolution of the peritonitis. Simultaneously, she had pancytopenia (2.9 million red blood cells/mm$^3$, WBC = 2150/mm$^3$, platelets = 8,000/mm$^3$) and positive antigenemia for cytomegalovirus (7/50,000 cells). Benznidazole and mycophenolate mofetil were suspended, and she was started on ganciclovir. There was clinical improvement and gradual recovery of erythrocytes, leukocytes and platelets. Mycophenolate mofetil was progressively reintroduced. She no longer received benznidazole.

Tacrolimus serum levels were between 3.4 and 7.5 ng/dl, and 4.4 ng/dl at the time of the skin lesions.

She remained very well clinically, without any other skin lesion. She had progressive improvement in graft function with plasma creatinine of 1.3 mg/dl at six months post-transplant. In her last visit at 14 months’ post-transplantation, she had no complaints and no significant changes on physical examination (BP = 128/80; normal heart and lung auscultation; a mild lower-limbs edema). She was on tacrolimus, mycophenolate mofetil, prednisone, furosemide, clonidine, amlodipine and enalapril. On that date, she had hemoglobin = 12 g/dL, hematocrit = 38%, WBC = 9100/mm$^3$; platelets = 217,000/mm$^3$, serum creatinine = 1.6 mg/dl, normal qualitative urinalysis and blood tacrolimus = 6.1 ng/dl.

A week later, she was admitted urgently because of severe chest pain radiating to the back; chest X-ray showed mediastinal widening and the echocardiogram showed dissecting aneurysm of the aorta. She was taken to surgery immediately, during which the type-A aortic dissection was confirmed, with inlet just above the left coronary ostium, and insufficient aortic valve. The patient developed an irreversible shock and died in the immediate postoperative period.
**DISCUSSION**

Asymptomatic reactivation of Chagas disease may occur in patients using immunosuppressants. Most cases are related to kidney or heart transplant, especially in the first year post-transplant. There may be fever, malaise, myocarditis, meningoencephalitis and skin lesions, and it can also mimic allograft rejection. Hardened erythematous plaques, areas of necrosis, nodules, panniculitis and ulcers are among the possible skin lesions. The patient described here had panniculitis in her left leg.

Serological tests have low sensitivity in immunocompromised patients. Parasitemia confirmation can be obtained by direct methods such as Strout, or indirect as xenodiagnosis or blood cultures. However, the sensitivity of these methods has also been lower than desired. Polymerase chain reaction techniques have shown greater sensitivity than traditional methods, even in immunocompromised patients. With signs and symptoms of reactivation, the finding of trypomastigotes parasites in the peripheral blood or cerebrospinal fluid confirms the diagnosis, just like amastigotes in compromised tissue biopsies.

Treatment can be done with nifurtimox (8 mg/kg/day) or benznidazole (5-7 mg/kg/day) for 60 days. For its lower toxicity, benznidazole is suggested as first choice treatment. Treatment should be discontinued when there is leucopenia (WBC < 2500/mm³) and neutropenia (<500/mm³). Transaminase increase (AST and ALT > 3 times the upper limit of normal) and severe leukopenia (leukocytes < 1000/mm³) led to intensive monitoring.

Although there are immunosuppressed patients with clinical improvement with treatment, it is known that Chagas disease brings high morbidity and mortality in such conditions.

Some authors suggest that similarly to diseases such as leprosy, tuberculosis and AIDS, whose only control was obtained with the combination of drugs, it would be interesting to study the effectiveness of two or more concurrent medications for the treatment of tripanosomiasis.

The anti-Trypanosoma effect of allopurinol alone or in combination with other medications has been suggested. However, there is no conclusive evidence or definitive recommendation in regards of its use as treatment or prophylaxis. An attractive point is their much lower toxicity profile when compared to benznidazole and nifurtimox. The described patient received allopurinol intended for prophylaxis at a dose of 100 mg per day, for she was still dependent on dialysis and then in the early stages of recovery from graft function with plasma creatinine around 3 mg/dl.

**REFERENCES**